Candesartan Cilexetil In Vitro-In Vivo Correlation: Predictive Dissolution as a Development Tool

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery and Formulation
• Pharmacokinetics

Background:

• Candesartan cilexetil is a Biopharmaceutic Classification System (BCS) class II drug with variable absorption.
• Developing an in vitro-in vivo correlation (IVIVC) is crucial for predicting drug performance and reducing bioequivalence failures.
• Existing in vitro dissolution tests may not adequately reflect in vivo behavior for immediate-release formulations.

Purpose of the Study:

• To develop a robust in vitro dissolution test for immediate-release candesartan cilexetil formulations.
• To establish an in vitro-in vivo correlation (IVIVC) as a predictive tool for bioequivalence studies.
• To optimize formulation selection and reduce failures in future bioequivalence trials.

Main Methods:

• Combined data from two bioequivalence studies to create a dataset for IVIVC development.
• Employed two-step and one-step approaches for IVIVC modeling.
• Utilized Loo-Riegelman deconvolution to determine oral fractions absorbed and USP apparatus II and IV for dissolution testing.
• Calculated f2 similarity factor and constructed Levy plots for time scaling.

Main Results:

• Experimental data confirmed candesartan cilexetil's solubility and permeability.
• A specific in vitro dissolution method using USP IV apparatus with a three-step pH buffer change (1.2, 4.5, 6.8) and 0.2% Tween 20 best reflected in vivo behavior.
• The developed IVIVC model successfully predicted in vivo dissolution differences.

Conclusions:

• The optimized in vitro dissolution test serves as an effective development tool for candesartan cilexetil formulations.
• The established IVIVC can be utilized as a risk-analysis tool for formulation selection in bioequivalence studies.
• This approach enhances the efficiency of drug development by minimizing the need for extensive in vivo testing.